Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2018-11-12 Regulatory Filings
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Chairman's Address and CEO Presentation to AGM 15 pages 11.2MB
Regulatory Filings
2018-11-12 English
Annual General Meeting - Results of Meeting 2 pages 134.8KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 13 November 2018 providing the results of the Annual General Meeting (AGM) of Invion Limited. It includes detailed voting results for each resolution passed at the AGM, referencing compliance with section 251AA of the Corporations Act 2001. The content focuses exclusively on the voting outcomes and resolutions from the AGM, without presenting any financial statements or management discussion. The document length is 4287 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-11-12 English
Invion collaborates to develop powerful skin cancer gel 2 pages 92.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing Invion Limited's collaboration to develop a new skin cancer gel using their Photosoft technology. It discusses plans for clinical trials, partnerships with development and testing companies, and the potential benefits of the new gel. There are no financial statements, regulatory filings, voting results, or management changes. The content focuses on product development and clinical trial plans rather than financial results or governance. It is not a report, transcript, or regulatory filing but rather a corporate announcement about a product development collaboration. This fits best under the category of a general regulatory announcement or miscellaneous corporate update, which corresponds to Regulatory Filings (RNS).
2018-11-06 English
Appendix 4C - September 2018 quarter 6 pages 94.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4C' and is described as a quarterly report for entities subject to Listing Rule 4.7B. It contains detailed financial data including consolidated statements of cash flows for the quarter ended 30 September 2018, cash reserves, net operating cash outflows, and estimated cash outflows for the next quarter. The document also includes compliance statements and notes referencing Australian Accounting Standards. The length of the document (over 11,000 characters) and the presence of substantive financial data confirm it is a financial report rather than a brief announcement or certification. Appendix 4C is a recognized quarterly cash flow report under ASX rules, which aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q1 2018
2018-10-28 English
CAT appoints R&G Pharma as CRO for nadolol in China 2 pages 89.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement detailing the selection of a contract research organisation (R&G Pharma) by Chronic Airway Therapeutics (a proposed spin-off from Invion Limited) to progress the development of nadolol in China. It discusses strategic partnerships, regulatory plans including pre-IND meetings with the China Food and Drug Administration, and shareholder information related to the spin-off. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about development and regulatory progress, not a financial report or detailed investor presentation. It is also not a notice of voting results or a management change. Given the content and length (5443 characters), it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about company activities and plans without substantive financial data or formal report content.
2018-09-26 English
New Photosoft formulation increased effect in ovarian cancer 2 pages 92.5KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement from Invion Limited dated 25 September 2018. It discusses new in vitro data on a new formulation of Photosoft therapy showing increased effectiveness against ovarian cancer cells. The announcement includes scientific results, future plans for animal and human clinical trials, and background information about the company and the therapy. There are no financial statements, regulatory certifications, voting results, or management changes. The content is primarily a corporate update on research progress and product development, typical of a Capital/Financing Update or general corporate announcement. Given the focus on new scientific data and development progress rather than financial results or regulatory filings, the best fit is Capital/Financing Update (CAP). The document length (6184 characters) and detailed content support this classification with high confidence.
2018-09-24 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.